Sanofi Announces Commitment to COP21

- Sanofi supports the mobilization to keep global warming below 2° Celsius to mitigate the impacts of climate change on health -

Paris, France - November 19, 2015 - Sanofi announced today its commitment to COP21, the United Nations conference on climate change, as an official partner, and its participation to Solutions COP21, a public exhibition in the heart of Paris. Following the World Health Organization (WHO) call to push the impact of climate change on human health to center stage, Sanofi has decided to actively contribute to COP21 in order to raise awareness on this issue, but also to take action to prevent its consequences.

“We need to urgently support the mobilization of the entire health community, public and private stakeholders, starting with life sciences companies, who are responsible for contributing to the advancement of health,” said Olivier Brandicourt, M.D., Chief Executive Officer, Sanofi. “If we act now, we can mitigate the consequences of climate change on the health of the world’s population. Health must be part of the Climate debate.”

Climate change is expected to cause approximately 250,000 additional deaths per year from malnutrition, malaria, diarrhea and heat stress, between 2030 and 2050, according to the World Health Organization (WHO). The direct effects of climate change on health include illness, death and morbidity during extreme weather events (heat waves, floods, droughts, hurricanes or storms). The indirect impacts go much further including the influence of climate on microbial populations, consequences on non-communicable diseases such as cardiovascular or respiratory diseases and distribution of vector-born diseases.

As highlighted in the 2015 Lancet Commission on Health and Climate Change Report, published in June, “the links between climate change, vector populations and hence malarial range and incidence may become significant in areas where the temperature is currently the limiting factor, possibly increasing the incidence of a disease that causes 660,000 deaths per year.”

Sanofi is actively engaged in a number of activities whose aim is to address health issues exacerbated by climate change:

- **Medications and Awareness**: Sanofi provides medicines and vaccines but also raises populations awareness, strengthens surveillance and enhances diagnostic and treatment capacity. In the field of malaria, for example, Sanofi has pursued strategic partnerships with National Malaria Control programs in several African countries to provide affordable medicines and to support local stakeholders in the prevention diagnosis and treatment of malaria.

- **Carbon Footprint**: Implementing a low carbon economy requires a collective effort. The health sector as a whole contributes between 3% and 5% to OECD countries emissions. Sanofi is committed to achieving a 20% reduction in CO2 emissions stemming (industrial and R&D sites) from 2010 to 2020. By the end of 2014, Sanofi achieved a 15% reduction.

- **Global Collaborations**: As a global healthcare leader, Sanofi is in a unique position to program the impacts of climate change on health on the public agenda in a collective
approach. That is why Sanofi is pursuing collaborations with governments, non-governmental organizations and the scientific community to find responses to limit the negative consequences of climate change on worldwide health.

Additionally and within the COP21, to mobilize the public and to help adapt to the consequences of climate change, Sanofi will launch a social networks campaign #HealthCOP21. From December 4th to 10th 2015, Sanofi will also host public on its booth at Solutions COP21, located in the Grand Palais, a public exhibition in the heart of Paris.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

**Media Relations**
Coralie Savin
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com

**Investor Relations**
Sébastien Martel
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com